

# Guillaume Moulis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2372249/guillaume-moulis-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88  
papers

1,492  
citations

20  
h-index

36  
g-index

119  
ext. papers

1,960  
ext. citations

4.6  
avg, IF

4.71  
L-index

#	Paper	IF	Citations
88	Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia.. <i>Platelets</i> , <b>2022</b> , 1-6	3.6	0
87	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network.. <i>British Journal of Haematology</i> , <b>2022</b> ,	4.5	
86	De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring.. <i>Blood</i> , <b>2022</b> , 139, 2561-2565	2.2	1
85	Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	1
84	Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry. <i>Blood</i> , <b>2021</b> , 138, 2079-2079	2.2	1
83	Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2021</b> , 22, 14	2.6	2
82	Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E291-E293	7.1	2
81	Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. <i>Fundamental and Clinical Pharmacology</i> , <b>2021</b> ,	3.1	1
80	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. <i>Fundamental and Clinical Pharmacology</i> , <b>2021</b> , 35, 194-203	3.1	9
79	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E43-E46	7.1	5
78	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , <b>2021</b> , 106, 1414-1422	6.6	2
77	Validation of Discharge Diagnosis of Sickle Cell Disease Vaso-Occlusive Episodes in the French Hospital Electronic Database. <i>Clinical Epidemiology</i> , <b>2021</b> , 13, 717-720	5.9	0
76	Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 703-705	4.5	7
75	Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 456-465	4.5	2
74	Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia. <i>Blood Advances</i> , <b>2020</b> , 4, 2136-2138	7.8	0
73	Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. <i>Blood Advances</i> , <b>2020</b> , 4, 1974-1977	7.8	3
72	Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. <i>British Journal of Haematology</i> , <b>2020</b> , 190, e276-e279	4.5	35

71	No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study. <i>British Journal of Haematology</i> , <b>2020</b> , 189, e137-e140	4.5	
70	Platelet counts of adults upon acute hospital admission to internal medicine units are a predictor of mortality. <i>Annals of Hematology</i> , <b>2020</b> , 99, 451-457	3	1
69	Correspondence on Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
68	Assessment of the Accuracy of Using Codes to Identify Systemic Sclerosis. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 1355-1359	5.9	4
67	Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease: A single-centre experience. <i>Haemophilia</i> , <b>2020</b> , 26, e34-e37	3.3	1
66	Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 79, 136-138	3.9	4
65	Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. <i>British Journal of Haematology</i> , <b>2020</b> , 190, e224-e229	4.5	48
64	Platelet Count within the Normal Range at Hospital Admission is Associated with Mortality in Patients with Community-Acquired Pneumonia. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 711-716	5.9	1
63	A New Tool to Assess the Epidemiology of Immune Thrombocytopenia: The Nordic Country Patient Registry for Romiplostim. <i>EClinicalMedicine</i> , <b>2019</b> , 14, 11-12	11.3	0
62	Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts. <i>Thrombosis Research</i> , <b>2019</b> , 178, 124-131	8.2	11
61	Immune Thrombocytopenia in Very Elderly Patients: Particularities in Presentation and Management. Results from the Multicenter Prospective Carmen-France Registry. <i>Blood</i> , <b>2019</b> , 134, 1091-1091	2.2	0
60	Validation of giant cell arteritis diagnosis code in the French hospital electronic database. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 60, e16-e17	3.9	5
59	Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP). <i>European Journal of Haematology</i> , <b>2018</b> , 100, 412-418	3.8	1
58	Early use of anakinra in adult-onset Still's disease myocarditis. <i>Scandinavian Journal of Rheumatology</i> , <b>2018</b> , 47, 511-512	1.9	5
57	Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E181-E184	7.1	1
56	Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 1830-1842	15.4	35
55	Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1541-1548	4.1	5
54	Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus. <i>Clinical Epidemiology</i> , <b>2018</b> , 10, 863-874	5.9	2

53	Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study. <i>Blood</i> , <b>2018</b> , 132, 3745-3745	2.2	1
52	Platelet Count upon Acute Hospital Admission to Internal Medicine Units Is a Predictor of Mortality in Adults: A Danish Cohort Study. <i>Blood</i> , <b>2018</b> , 132, 3578-3578	2.2	
51	Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. <i>Fundamental and Clinical Pharmacology</i> , <b>2018</b> , 32, 108-113	3.1	14
50	Prevalence of thrombocytopenia and thrombocytosis upon acute hospital admission to internal medicine units. A cross-sectional study in Denmark. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 57, e34-e37	3.9	4
49	Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 785-791	15.4	14
48	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 493-500	7.1	33
47	Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 578-586	2.6	12
46	Seasonal variations of incident primary immune thrombocytopenia in adults: An ecological study. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, e26-e28	3.9	3
45	Effect of pregnancy in women with a history of primary immune thrombocytopenia considered as cured. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 46, e15-e16	3.9	2
44	Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 344-349	3.8	13
43	Positive predictive value of hospital discharge diagnosis code to identify immunoglobulin A vasculitis in France: A validation study. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 43, e18-e19	3.9	9
42	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. <i>American Journal of Hematology</i> , <b>2016</b> , 91, E499-E501	7.1	17
41	Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. <i>Fundamental and Clinical Pharmacology</i> , <b>2016</b> , 30, 616-624	3.1	58
40	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 203-9	13.6	32
39	Cryofibrinogenemia and risk of cancer in cryoglobulinemic patients without vasculitis criteria. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 28, e10-2	3.9	2
38	Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French National Health Insurance Database. <i>Blood</i> , <b>2016</b> , 128, 4764-4764	2.2	1
37	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , <b>2016</b> , 30, 162-71	3.1	11
36	Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 296-301	4	107

35	Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 785-9	2.6	19
34	Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 32, e21-2	3.9	10
33	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , <b>2016</b> , 128, 1625-30	2.2	50
32	Searching for a polypharmacy threshold associated with frailty. <i>Journal of the American Medical Directors Association</i> , <b>2015</b> , 16, 259-61	5.9	27
31	Exposure to atropinic drugs and frailty status. <i>Journal of the American Medical Directors Association</i> , <b>2015</b> , 16, 253-7	5.9	30
30	French health insurance databases: What interest for medical research?. <i>Revue De Medecine Interne</i> , <b>2015</b> , 36, 411-7	0.1	204
29	Cryofibrinogenemia: a marker of severity of cryoglobulinemic vasculitis. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 916-21	2.4	10
28	Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase. <i>Drug Safety</i> , <b>2015</b> , 38, 1179-86	5.1	20
27	Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 168-73	13.6	13
26	Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: comment. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1521-2	15.4	2
25	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. <i>Rheumatology</i> , <b>2015</b> , 54, 1852-7	3.9	29
24	Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 301-5	7.1	19
23	Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort. <i>Blood</i> , <b>2015</b> , 126, 3473-3473	2.2	2
22	Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study. <i>Blood</i> , <b>2015</b> , 126, 9-9	2.2	2
21	Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142217	3.7	16
20	Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 41-6	7.1	33
19	Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. <i>Rheumatology</i> , <b>2014</b> , 53, 1465-9	3.9	17
18	Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies. <i>Therapie</i> , <b>2014</b> , 69, 437-48	3.8	18

17	Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. <i>Blood</i> , <b>2014</b> , 124, 3308-15	2.2	170
16	Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French Pharmacovigilance assessment. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 777-80	3.9	19
15	Imaging in Erdheim-Chester disease: classic features and new insights. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, 410-4	2.2	6
14	Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. <i>European Journal of Haematology</i> , <b>2013</b> , 90, 438-9	3.8	7
13	Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1670-1		2
12	Biologics in relapsing polychondritis: a case series. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 937-9	2.2	16
11	Trends of reporting of serious vs. non-serious adverse drug reactions over time: a study in the French Pharmacovigilance Database. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 201-4	3.8	25
10	Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 221-2	2.8	6
9	Drug-induced immune thrombocytopenia: a descriptive survey in the French Pharmacovigilance database. <i>Platelets</i> , <b>2012</b> , 23, 490-4	3.6	20
8	Cancer risk of anti-TNF- $\alpha$ at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. <i>PLoS ONE</i> , <b>2012</b> , 7, e48991	3.7	56
7	Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 314-9	2.6	9
6	Reply to the commentary by Onuigbo on the article "Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins. A case-control study". <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 300-1	2.6	
5	Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. <i>Lupus</i> , <b>2012</b> , 21, 885-9	2.6	22
4	Scrofula, the king's evil. <i>Cmaj</i> , <b>2012</b> , 184, 1061	3.5	4
3	Very late relapse of dapsone-induced methaemoglobinemia. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 645-6	2.8	8
2	Acquired factor VIII haemophilia following influenza vaccination. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1069-70	2.8	15
1	May anakinra be used earlier in adult onset Still disease?. <i>Clinical Rheumatology</i> , <b>2010</b> , 29, 1199-200	3.9	23